Skip to content
TickerMagic

COHANCE LIFESCIENCES LTD

COHANCENSEHealthcare
₹459.45
+3.05 (+0.67%) · EOD 2026-11-20

Our verdict

Sell

Momentum (63/100) does the heavy lifting; financial trend (0/100) is the drag.

ExpensiveHealth AOvervalued
Quality 43Momentum 63Value 15Trend 0The Spark ↓

Our fair value

Overvalued by 39%
₹282.45down 38.52%
Price ₹459Range ₹230 – ₹486

Buy-below (20% margin of safety): ₹225.96

The bottom line

Our blended model reads COHANCE LIFESCIENCES LTD as a Sell at 30/100. At ₹459.45 it trades above our blended DCF and relative-multiples fair value of ₹282.45, about 39% downside to that estimate — we read it as overvalued by 39%. On 99.0x trailing earnings it sits pricier than the Healthcare median of about 37.4x. The price is about 22% below its 52-week high of ₹589.3 and 64% above the low of ₹279.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹516.78 implies about 12% upside across 9 analysts. It clears 6 of 13 investability checks, with durability 43, valuation 29 and momentum 63 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹282.45down 38.52%
Overvalued by 39%
Price ₹459.45Range ₹229.73–₹485.54
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹225.96.

Analyst views

9 analysts4 buy · 1 hold · 4 sell
12-month consensus target₹516.78up 12.48%

1-year price

EOD · 2026-11-20
1D
up 0.67%
1W
down 2.59%
1M
up 0.38%
3M
up 0.93%
6M
up 7.26%
1Y
—

52-week range

-22.03% from the 52-week high.

Trend check
Above 50-DMA₹452Above 200-DMA₹412

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Sell30
A
Financial health 100/100
Altman Z 7.31 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Our scores

Durability43
Valuation29
Momentum63

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 6 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 3.8%
  • Pass: Low debt (D/E < 0.5): 0.10x
  • Pass: Positive free cash flow
  • Fail: Revenue growth > 10%: -26%
  • Fail: Earnings growing: -89%
  • Fail: Net margin ≥ 10%: 7.9%
  • Pass: Current ratio > 1.5: 2.83
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 7.31
  • Fail: Piotroski ≥ 7: 4/9

Quarterly results

Revenue · 4Q2025
₹545 Cr
Net profit
₹21 Cr
Margin
4%
1Q2025
2Q2025
3Q2025
4Q2025
Revenue Net profitLatest revenue QoQ -2%

Annual financials

Revenue · 2025
₹2,610 Cr
Net profit
₹546 Cr
Margin
21%
2022
2023
2024
2025
Revenue Net profitLatest revenue YoY +148%

Shareholding

  • Promoter64.0%
  • Institutions25.5%
  • Public & other10.6%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹17,705 Cr
P/E ratio
99.0
P/B ratio
4.53
EPS (TTM)
₹4.67
ROE
3.8%
Debt / Equity
0.10x
Profit margin
7.9%
Free cash flow
₹49 Cr
52-week high
₹589.3
-22.03% from high
52-week low
₹279.9
Dividend yield
—
Beta
0.57
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 7.31.

Bear case

Weaknesses

  • Low return on equity (3.8%).

Threats

  • Earnings contracting year on year.
  • Rich valuation versus sector peers.
  • Trades ~39% above our estimated fair value.

About COHANCE LIFESCIENCES LTD

Cohance Lifesciences Limited provides contract research, development, and manufacturing services for new chemical entities, active pharmaceutical ingredients, specialty chemicals, and formulated drugs across India, the United States, Europe, and other markets. The company produces small molecule APIs, advanced intermediates, starting materials, antibody drug conjugates, and high-purity oligonucleotide building blocks including phosphoramidites and nucleosides.

COHANCE LIFESCIENCES LTD — frequently asked questions

Is COHANCE LIFESCIENCES LTD a buy, hold or sell?

TickerMagic currently rates COHANCE LIFESCIENCES LTD (COHANCE) a Sell, based on a blended score of 30/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is COHANCE LIFESCIENCES LTD's fair value?

Our blended DCF and relative-valuation model estimates COHANCE LIFESCIENCES LTD's fair value at about ₹282.45, versus a current price of ₹459.45 — roughly 39% downside. On that basis the stock looks overvalued by 39%.

Is COHANCE LIFESCIENCES LTD financially healthy?

COHANCE LIFESCIENCES LTD scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.

How has COHANCE LIFESCIENCES LTD's share price performed?

COHANCE LIFESCIENCES LTD is up 1% over three months, and last traded at ₹459.45. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.